
Published
04 May 2011 | By Kinapse
In today’s challenging business environment, many innovative life sciences companies are raising questions about the return on investment of internal resources and external expenditures. These questions are now being asked of Medical Affairs Leaders. It is very challenging to measure Medical Affairs ‘value’ in this way, and we see many instances of Medical Affairs investments being constrained in light of general budgetary pressures. We argue that this is a short-sighted and potentially hazardous trend as we believe that Medical Affairs capabilities must evolve to be at the centre of life sciences companies’ therapeutic innovation, product development and stakeholder interactions.
As a registered user of PBR you can skip the majority of this form. Registration is FREE so register now or log in if you're already a member.
Fill In Details
By clicking the 'download white paper' button you agree to pass your details as shown to the white paper advertiser. The enquirer also permits the advertiser to follow up the enquiry by phone or email. PBR is in no way responsible for further communication between parties.
Fields marked * are compulsory
Fields marked * are compulsory